1
|
Faundes V, Repetto GM, Valdivia LE. Discovery of novel genetic syndromes in Latin America: Opportunities and challenges. Genet Mol Biol 2024; 47Suppl 1:e20230318. [PMID: 38466870 DOI: 10.1590/1678-4685-gmb-2023-0318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Accepted: 02/06/2024] [Indexed: 03/13/2024] Open
Abstract
Latin America (LatAm) has a rich and historically significant role in delineating both novel and well-documented genetic disorders. However, the ongoing advancements in the field of human genetics pose challenges to the relatively slow adaption of LatAm in the field. Here, we describe past and present contributions of LatAm to the discovery of novel genetic disorders, often referred as novel gene-disease associations (NGDA). We also describe the current methodologies for discovery of NGDA, taking into account the latest developments in genomics. We provide an overview of opportunities and challenges for NGDA research in LatAm considering the steps currently performed to identify and validate such associations. Given the multiple and diverse needs of populations and countries in LatAm, it is imperative to foster collaborations amongst patients, indigenous people, clinicians and scientists. Such collaborative effort is essential for sustaining and enhancing the LatAm´s contributions to the field of NGDA.
Collapse
Affiliation(s)
- Víctor Faundes
- Universidad de Chile, Instituto de Nutrición y Tecnología de los Alimentos, Laboratorio de Genética y Enfermedades Metabólicas, Santiago, Chile
| | - Gabriela M Repetto
- Universidad del Desarrollo, Facultad de Medicina, Instituto de Ciencias e Innovación en Medicina, Centro de Genética y Genómica, Programa de Enfermedades Raras, Santiago, Chile
| | - Leonardo E Valdivia
- Universidad Mayor, Facultad de Ciencias, Centro de Biología Integrativa, Santiago, Chile
- Universidad Mayor, Facultad de Ciencias, Escuela de Biotecnología, Santiago, Chile
| |
Collapse
|
2
|
Sosa-Macías M, Fricke-Galindo I, Fariñas H, Monterde L, Ruiz-Cruz ED, Molina-Guarneros J, Tarazona-Santos E, Rodrigues-Soares F, Galaviz-Hernández C, Peñas-Lledó E, Moya G, Lara-Riegos J, Terán E, Hernández I, Ramírez-Roa R, Altamirano-Tinoco C, López-López M, García-Ortiz JE, LLerena A. Pharmacogenetics: ethnicity, treatment and health in Latin American populations. Pharmacogenomics 2023; 24:489-492. [PMID: 37529900 DOI: 10.2217/pgs-2023-0098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/03/2023] Open
Abstract
The Ibero-American Network of Pharmacogenetics and Pharmacogenomics (RIBEF) studies Latin American populations to benefit from the implementation of personalized medicine. Since 2006, it has studied ethnicity to apply pharmacogenetics knowledge in autochthonous populations of Latin America, considering ancestral medicine. The meeting 'Pharmacogenetics: ethnicity, Treatment and Health in Latin American Populations' was held in Mexico City, Mexico, and presented the relevance of RIBEF collaboration with Latin American researchers and the governments of Mexico, Spain and the Autonomous Community of Extremadura. The results of 17 years of uninterrupted work by RIBEF, the Declaration of Mérida/T'Hó and the call for the Dr José María Cantú Award for studies focused on the pharmacogenetics of native populations in Latin America were presented.
Collapse
Affiliation(s)
- Martha Sosa-Macías
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- IPN Instituto Politécnico Nacional CIIDIR-Unidad Durango, Mexico
| | - Ingrid Fricke-Galindo
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
| | - Humberto Fariñas
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- INUBE Instituto Universitario de Investigación Biosanitaria de Extremadura, University of Extremadura, Extremadura, Spain
- SIFF Ibero American Society of Pharmacogenetics & Pharmacogenomics
| | | | | | - Juan Molina-Guarneros
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- UNAM Universidad Nacional Autónoma de Mexico, Mexico City, Mexico
| | - Eduardo Tarazona-Santos
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- UFMG Universidade Federal de Minas Gerais, Instituto de Ciencias Biológicas, Belo Horizonte, Brazil
- UPCH Universidad Peruana Cayetano Heredia, Lima, Peru
| | - Fernanda Rodrigues-Soares
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- UFTM Universidade Federal do Triangulo Mineiro, Uberaba, Brazil
| | - Carlos Galaviz-Hernández
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- IPN Instituto Politécnico Nacional CIIDIR-Unidad Durango, Mexico
| | - Eva Peñas-Lledó
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- INUBE Instituto Universitario de Investigación Biosanitaria de Extremadura, University of Extremadura, Extremadura, Spain
| | - Graciela Moya
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- UCA Universidad Católica Argentina, Buenos Aires, Argentina
| | - Julio Lara-Riegos
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- UADY Universidad Autónoma de Yucatán, Mexico
| | - Enrique Terán
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- USFQ Universidad San Francisco de Quito, Ecuador
| | - Isabel Hernández
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- PUCE Pontificia Universidad Católica del Ecuador, Ecuador
| | - Ronald Ramírez-Roa
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- SIFF Ibero American Society of Pharmacogenetics & Pharmacogenomics
| | - Catalina Altamirano-Tinoco
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- UNAN Universidad Nacional Autónoma de Nicaragua-León, Nicaragua
| | - Marisol López-López
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- UAM Universidad Autónoma Metropolitana, Mexico City, Mexico
| | - José Elías García-Ortiz
- CIBO, Centro de Investigación Biomédica de Occidente-IMSS, Guadalajara, Mexico
- RELAGH Latin American Network of Human Genetics
| | - Adrián LLerena
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- INUBE Instituto Universitario de Investigación Biosanitaria de Extremadura, University of Extremadura, Extremadura, Spain
| |
Collapse
|
3
|
Fricke-Galindo I, LLerena A. Pharmacogenetics and ethnicity: "Dr. José María Cantú" award announcement. Drug Metab Pers Ther 2023:dmdi-2023-0037. [PMID: 37155924 DOI: 10.1515/dmpt-2023-0037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Affiliation(s)
- Ingrid Fricke-Galindo
- HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City, Mexico
| | - Adrián LLerena
- INUBE Biosanitary University Research Institute, University of Extremadura, Badajoz, Spain
- University of Extremadura Medical School, Badajoz, Spain
- CIBERSAM, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
4
|
Sosa-Macias M, Moya GE, LLerena A, Ramírez R, Terán E, Peñas-LLedó EM, Tarazona-Santos E, Galaviz-Hernández C, Céspedes-Garro C, Acosta H. Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014). Pharmacogenomics 2015; 16:673-6. [PMID: 25929854 DOI: 10.2217/pgs.15.32] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
MESTIFAR 2014 28-30 November 2014, Panama City, Panama The CEIBA consortium was created within the Ibero-American network of Pharmacogenetics (RIBEF) to study population pharmacogenetics. The current status of these initiatives and results of the MESTIFAR project were analyzed in Panama, 28-30 November 2014. The MESTIFAR project focused on studying CYPs genetic polymorphisms in populations of different ethnic origin. So far, more than 6000 healthy volunteers have been evaluated, making this one of the largest population pharmacogenomic studies worldwide. Three symposia were organized, 'Pharmacogenetics of indigenous and mestizos populations and its clinical implications', 'Methodological innovation in pharmacogenetics and its application in health', and 'General discussion and concluding remarks', about mechanisms and proposals for training, diffusion of pharmacogenetics for Spanish- and Portuguese-speaking health professionals, and 'bench to bedside' pilot projects.
Collapse
Affiliation(s)
| | | | | | - Ronald Ramírez
- 5UNAN-León, Universidad Nacional Autónoma de Nicaragua, León, Nicaragua
| | - Enrique Terán
- 6USFQ, Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Quito, Ecuador
| | | | | | | | | | | |
Collapse
|